Evolus to Participate in The Leerink Partners Global Healthcare Conference
News > Business News
Audio By Carbonatix
8:00 AM on Wednesday, February 25
The Associated Press
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb 25, 2026--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.
The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau ® and Nuceiva ® are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260225101738/en/
CONTACT: Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email:[email protected]
Media:
Email:[email protected]
KEYWORD: CALIFORNIA FLORIDA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: COSMETICS RETAIL HEALTH CONSUMER WOMEN OTHER HEALTH PHARMACEUTICAL
SOURCE: Evolus
Copyright Business Wire 2026.
PUB: 02/25/2026 08:00 AM/DISC: 02/25/2026 08:02 AM
http://www.businesswire.com/news/home/20260225101738/en